A Single Dose, Open-label, Randomized Two-period Crossover Study in Healthy Young Subjects to Assess the Absolute Bioavailability of Ipragliflozin
Latest Information Update: 14 Jan 2020
At a glance
- Drugs Ipragliflozin (Primary) ; Ipragliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Astellas Pharma Europe Ltd
Most Recent Events
- 12 Jun 2012 New trial record